Corbus Pharmaceuticals Holdings Inc

NASDAQ:CRBP   2:26:28 PM EDT
1.94
-0.06 (-2.76%)
Other Pre-Announcement

Corbus Pharmaceuticals Licenses Two Integrin Targeting Mabs Further Expanding Pipeline Into Cancer And Fibrotic Diseases

Published: 06/01/2021 13:36 GMT
Corbus Pharmaceuticals Holdings Inc (CRBP) - Corbus Pharmaceuticals Licenses Two Integrin Targeting Mabs Further Expanding Pipeline Into Cancer and Fibrotic Diseases.
Corbus Pharmaceuticals Holdings Inc - High Potency Anti-ΑvΒ8 Mab and Anti-ΑvΒ6/ΑvΒ8 Mab Expected to Start Phase 1 Testing in 2022.
Corbus Pharmaceuticals Holdings Inc - Capital and Resources in Place to Advance Multiple Programs Into Clinical Development.
Corbus Pharmaceuticals Holdings Inc - Expects to Have Four Compounds Other Than Lenabasum in Phase 1 Testing in 2022.
Corbus Pharmaceuticals Holdings Inc - Had $125 Million of Cash, Investments on Hand, As of March 31, 2021.
Corbus Pharmaceuticals Holdings - Cash, Investments on Hand, is Expected to Fund Operations Into Q1 of 2024, Based on Current Planned Expenditures.
Corbus Pharmaceuticals Holdings Inc - Under Licensing Agreements, Co Will Pay $2 Million Upfront.
Corbus - Under Terms, Co Will Make Potential Development, Sales Milestone Payments Totaling Up to $206 Million, Pay Low Single-digit Royalties on Sales.